Sign in Subscribe
Biotechnology industries

InNexus Biotechnology and Mayo Clinic Collaborate on Promising New Medicines

Strategic Insights

— 1 min read

In a significant step towards developing innovative treatments for life-threatening diseases, InNexus Biotechnology, Inc. has partnered with the renowned Mayo Clinic in a multiyear collaborative research agreement. This collaboration aims to drive the leading science of monoclonal antibody development, focusing on cancer, cardiovascular disease, and other challenging conditions. By combining their expertise, InNexus and Mayo Clinic hope to accelerate the creation of novel products that will provide clinicians with more comprehensive treatment choices.

Key Takeaways:

  • InNexus Biotechnology and Mayo Clinic have entered a multiyear collaborative research agreement to advance monoclonal antibody development and create new medicines for cancer, cardiovascular disease, and other diseases.
  • The collaboration aims to synergize the strengths of both organizations and focus on creating new antibody-based therapies.
  • The mission of the partnership is to develop new therapies and leverage the innovative work of InNexus in developing SuperAntibodies.
  • The agreement is expected to generate an accelerated stream of novel products that will provide clinicians with new treatment choices.
  • Charles Morgan, president & CEO of InNexus, emphasized the significance of combining forces with Mayo Clinic to further InNexus' innovative work in developing SuperAntibodies.
  • InNexus Biotechnology, Inc. is a company dedicated to developing innovative therapies.
  • Mayo Clinic is a renowned medical institution with expertise in various fields, including research and development.
  • Monoclonal antibodies are specialized proteins that play a crucial role in the immune system and can be used to develop targeted therapies.
  • SuperAntibodies are a class of antibodies developed by InNexus that have shown great promise in treating various diseases.

Statistics:

  • No specific statistics were mentioned in the article.
  • However, it is stated that the collaboration aims to develop new therapies for cancer, cardiovascular disease, and other diseases.

Sources:

  • Health & Medicine Week editors from staff and other reports, Copyright 2005, Health & Medicine Week via NewsRx.com.

Read more